Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial

Conditions

chronic, life-limiting disease, Serious

Brief summary

Self-rated breathlessness (ESAS-r) [21, 22] change from baseline at 60 minutes after the treatment was administered.

Detailed description

Self-rated breathlessness (ESAS-r), change from baseline at 30 minutes after the treatment was administered, Change from baseline for other symptoms (pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, wellbeing) self-rated using the ESAS-r, change from baseline at 60 minutes after the treatment was administered, Safety measures (SpO2, breathing rate, and level of consciousness [GCS]) change from baseline at 60 minutes after the treatment was administered, Adverse drug reactions (ADRs), defined as adverse events assessed as possibly or probably related to the investigational medicinal product and excluding events attributable to the natural course of the underlying disease, will be recorded at 60 minutes after treatment administration, prior to the next dose, and at the end of the trial., Date, place and cause(s) of death up to three months after date of first randomization in the trial

Related papers

No related papers found yet.

Interventions

DRUGNatriumklorid Fresenius Kabi 9 mg/ml infusionsvätska

DRUGlösning

DRUGMorfin Abcur

DRUG10 mg/ml

DRUGinjektionsvätska

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Self-rated breathlessness (ESAS-r) [21, 22] change from baseline at 60 minutes after the treatment was administered.	—

Secondary

Measure	Time frame
Self-rated breathlessness (ESAS-r), change from baseline at 30 minutes after the treatment was administered, Change from baseline for other symptoms (pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, wellbeing) self-rated using the ESAS-r, change from baseline at 60 minutes after the treatment was administered, Safety measures (SpO2, breathing rate, and level of consciousness [GCS]) change from baseline at 60 minutes after the treatment was administered, Adverse drug reactions (ADRs), defined as adverse events assessed as possibly or probably related to the investigational medicinal product and excluding events attributable to the natural course of the underlying disease, will be recorded at 60 minutes after treatment administration, prior to the next dose, and at the end of the trial., Date, place and cause(s) of death up to three months after date of first randomization in the trial	—

Measure

Time frame

Self-rated breathlessness (ESAS-r), change from baseline at 30 minutes after the treatment was administered, Change from baseline for other symptoms (pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, wellbeing) self-rated using the ESAS-r, change from baseline at 60 minutes after the treatment was administered, Safety measures (SpO2, breathing rate, and level of consciousness [GCS]) change from baseline at 60 minutes after the treatment was administered, Adverse drug reactions (ADRs), defined as adverse events assessed as possibly or probably related to the investigational medicinal product and excluding events attributable to the natural course of the underlying disease, will be recorded at 60 minutes after treatment administration, prior to the next dose, and at the end of the trial., Date, place and cause(s) of death up to three months after date of first randomization in the trial

—

Outcome results

None listed